David E. Kandzari

28.4k total citations · 4 hit papers
316 papers, 10.8k citations indexed

About

David E. Kandzari is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David E. Kandzari has authored 316 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 234 papers in Cardiology and Cardiovascular Medicine, 233 papers in Surgery and 72 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David E. Kandzari's work include Coronary Interventions and Diagnostics (196 papers), Antiplatelet Therapy and Cardiovascular Diseases (75 papers) and Acute Myocardial Infarction Research (72 papers). David E. Kandzari is often cited by papers focused on Coronary Interventions and Diagnostics (196 papers), Antiplatelet Therapy and Cardiovascular Diseases (75 papers) and Acute Myocardial Infarction Research (72 papers). David E. Kandzari collaborates with scholars based in United States, United Kingdom and Germany. David E. Kandzari's co-authors include Martin B. Leon, Laura Mauri, Raymond R. Townsend, Deepak L. Bhatt, Sidney A. Cohen, George L. Bakris, Krishna J. Rocha‐Singh, Ralph B. D’Agostino, William W. O’Neill and John M. Flack and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

David E. Kandzari

295 papers receiving 10.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Controlled Trial of Renal Denervation for Resistant Hypertension

2014 1.4k citations Deepak L. Bhatt, David E. Kandzari et al. profile →
Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation

2006 623 citations David E. Kandzari et al. profile →
A Percutaneous Treatment Algorithm for Crossing Coronary Chronic Total Occlusions

2012 352 citations Emmanouil S. Brilakis, R. Michael Wyman et al. JACC: Cardiovascular Interventions profile →
Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial

2022 168 citations Felix Mahfoud, David E. Kandzari et al. profile →

Peers

Countries citing papers authored by David E. Kandzari

Since Specialization

Citations

This map shows the geographic impact of David E. Kandzari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Kandzari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Kandzari more than expected).

Fields of papers citing papers by David E. Kandzari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Kandzari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Kandzari. The network helps show where David E. Kandzari may publish in the future.

Co-authorship network of co-authors of David E. Kandzari

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Kandzari. A scholar is included among the top collaborators of David E. Kandzari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Kandzari. David E. Kandzari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term outcomes following radiofrequency renal denervation: meta-analysis of 18 reports 2025 ·European Journal of Preventive Cardiology ·Felix Mahfoud, David E. Kandzari, Markus P. Schlaich, (unknown), Lucas Lauder, Luís M. Ruilope, Krzysztof Narkiewicz, Bryan Williams, Douglas A. Hettrick, Te‐Hsin Lung, Flavio Ribichini, Joachim Weil, Faisal Sharif, Giuseppe Mancia, Michael Böhm	1
2	Novel approaches to define responders to interventional treatment in hypertension: insights from the SPYRAL HTN-OFF and HTN-ON MED trials 2024 ·Hypertension Research ·Roland E. Schmieder, Douglas A. Hettrick, Michael Böhm, David E. Kandzari, Kazuomi Kario, Felix Mahfoud, Konstantinos Tsioufis, Michael A. Weber, Murray Esler, Raymond R. Townsend	2
3	One-Month Dual Antiplatelet Therapy in High Bleeding Risk Asian Patients Undergoing Percutaneous Coronary Intervention　― Onyx ONE Clear 2-Year Results ― 2024 ·Circulation Reports ·Jeehoon Kang, (unknown), (unknown), Seung‐Ho Hur, Chor Cheung Tam, Yangsoo Jang, In‐Ho Chae, David E. Kandzari, Ajay J. Kirtane, Azeem Latib, Elvin Kedhi, (unknown), (unknown), Stephan Windecker, Gregg W. Stone, Hyo‐Soo Kim	0
4	Incidence, Predictors, and Impact of Hospital Readmission After Revascularization for Left Main Coronary Disease 2024 ·Journal of the American College of Cardiology ·(unknown), Bahira Shahim, Ovidiu Dressler, Björn Redfors, Marie‐Claude Morice, John D. Puskas, David E. Kandzari, Dimitri Karmpaliotis, W. Morris Brown, Nicholas Lembo, Adrian Banning, A. Pieter Kappetein, Patrick W. Serruys, Joseph F. Sabik, Gregg W. Stone	2
5	Major Bleeding and Mortality After Revascularization of Left Main Disease 2024 ·Journal of the American College of Cardiology ·Gennaro Giustino, Joseph F. Sabik, Patrick W. Serruys, John D. Puskas, Dimitri Karmpaliotis, David E. Kandzari, Marie‐Claude Morice, Michael Ragosta, Zixuan Zhang, Ovidiu Dressler, Björn Redfors, Ori Ben‐Yehuda, Samin K. Sharma, A. Pieter Kappetein, Gregg W. Stone	0
6	POOLED, LONG-TERM ANALYSIS OF THE GLOBAL SYMPLICITY CLINICAL TRIAL PROGRAM OF RADIOFREQUENCY RENAL DENERVATION FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION 2024 ·Journal of Hypertension ·Felix Mahfoud, Raymond R. Townsend, Giuseppe Mancia, David E. Kandzari, Robert Whitbourn, Deepak L. Bhatt, George L. Bakris, Kazuomi Kario, Martin Fahy, Michael Böhm	2
7	SIGNIFICANT NIGHTTIME BLOOD PRESSURE REDUCTIONS AFTER RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION: POOLED ANALYSIS OF THE SPYRAL HTN TRIALS 2024 ·Journal of Hypertension ·(unknown), Felix Mahfoud, Raymond R. Townsend, David E. Kandzari, Michael A. Weber, Roland E. Schmieder, Konstantinos Tsioufis, Martin Fahy, Michael Böhm	1
8	Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis 2024 ·medRxiv ·Davor Vukadinović, Lucas Lauder, David E. Kandzari, Deepak L. Bhatt, Ajay J. Kirtane, Elazer R. Edelman, Roland E. Schmieder, Michel Azizi, Michael Böhm, Felix Mahfoud	1
9	Comparison of Ridaforolimus‐Eluting and Zotarolimus‐Eluting Coronary Stents: 5‐Year Outcomes From the BIONICS and NIREUS Trials 2024 ·Journal of the American Heart Association ·(unknown), Pieter C. Smits, Michael P. Love, Gregg W. Stone, David E. Kandzari, Björn Redfors, (unknown), Maayan Konigstein	0
10	Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial 2024 ·Circulation ·David E. Kandzari, Michael A. Weber, Atul Pathak, James P. Zidar, Manish Saxena, Shukri David, Roland E. Schmieder, Adam Janas, (unknown), Alexandre Persu, Farrell O. Mendelsohn, Koen Ameloot, Malcolm Foster, Tim A. Fischell, Helen Parise, Felix Mahfoud	26
11	Paclitaxel‐coated versus sirolimus‐coated balloon angioplasty for coronary artery disease: A systematic review and meta‐analysis 2024 ·Catheterization and Cardiovascular Interventions ·Doosup Shin, (unknown), Evan Shlofmitz, Bruno Scheller, Azeem Latib, David E. Kandzari, Azfar Zaman, Darren Mylotte, (unknown), Sarah Malik, Koshiro Sakai, Allen Jeremias, Jeffrey W. Moses, (unknown), Gregg W. Stone, Ziad A. Ali	7
12	Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis 2024 ·Journal of the American Heart Association ·Syed Hamza Mufarrih, Nada Qaisar Qureshi, (unknown), (unknown), Eric A. Secemsky, Michael J. Bloch, Jay Giri, Debbie L. Cohen, S. Rajesh, Dmitriy N. Feldman, Khaldoon Alaswad, Ajay J. Kirtane, David E. Kandzari, Herbert D. Aronow	4
13	Provisional Strategy for Left Main Stem Bifurcation Disease 2023 ·JACC: Cardiovascular Interventions ·Valeria Paradies, Adrian Banning, Davide Cao, Alaide Chieffo, Joost Daemen, Roberto Diletti, David Hildick‐Smith, David E. Kandzari, Ajay J. Kirtane, Roxana Mehran, Duk‐Woo Park, Giuseppe Tarantini, Pieter C. Smits, Nicolas M. Van Mieghem	10
14	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions 2021 ·Contemporary Clinical Trials Communications ·Michael Böhm, Martin Fahy, Graeme L. Hickey, Stuart Pocock, Sandeep Brar, Vanessa DeBruin, Michael A. Weber, Felix Mahfoud, David E. Kandzari	6
15	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications 2021 ·American Heart Journal ·Felix Mahfoud, Michael A. Weber, Roland E. Schmieder, Melvin D. Lobo, Peter J. Blankestijn, Alexandre Persu, Tim A. Fischell, Helen Parise, Atul Pathak, David E. Kandzari	19
16	Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study 2021 ·Catheterization and Cardiovascular Interventions ·David E. Kandzari, Khaldoon Alaswad, Farouc A. Jaffer, Emmanouil S. Brilakis, Kevin Croce, Kathleen E. Kearney, Anthony Spaedy, Robert W. Yeh, Craig A. Thompson, William Nicholson, R. Michael Wyman, Robert F. Riley, Alexandra J. Lansky, Christopher E. Buller, Dimitrios Karmpaliotis	0
17	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension 2021 ·Circulation Cardiovascular Interventions ·Felix Mahfoud, Horst Sievert, Stefan Bertog, Lucas Lauder, Sebastian Ewen, Jean‐Philippe Lengelé, Wojciech Wojakowski, Roland E. Schmieder, Markus van der Giet, Michael A. Weber, David E. Kandzari, Helen Parise, Tim A. Fischell, Atul Pathak, Alexandre Persu	9
18	Orbital atherectomy for the treatment of severely calcified coronary lesions: evidence, technique, and best practices 2017 ·Expert Review of Medical Devices ·Evan Shlofmitz, Brad J. Martinsen, Michael S. Lee, Sunil V. Rao, Philippe Généreux, (unknown), Jeffrey W. Chambers, Ajay J. Kirtane, Emmanouil S. Brilakis, David E. Kandzari, Samin K. Sharma, Richard Shlofmitz	63
19	Influence of Total Coronary Occlusion on Clinical Outcomes (from the Bypass Angioplasty Revascularization Investigation 2 DiabetesTrial) 2016 ·The American Journal of Cardiology ·Abdulla A. Damluji, (unknown), (unknown), Mohammed Salim Al‐Damluji, Carlos E. Alfonso, (unknown), Steven P. Marso, Ian C. Gilchrist, Mauro Moscucci, David E. Kandzari, Mauricio G. Cohen	15
20	The efficacy and safety of the "hybrid" approach to coronary chronic total occlusions: insights from a contemporary multicenter US registry and comparison with prior studies. 2014 ·PubMed ·Georgios Christopoulos, Rohan Menon, Dimitri Karmpaliotis, Khaldoon Alaswad, William Lombardi, (unknown), Vishal Patel, Bavana V. Rangan, Anna Kotsia, Nicholas Lembo, David E. Kandzari, Harold Carlson, Santiago García, Subhash Banerjee, Craig A. Thompson, Emmanouil S. Brilakis	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact